Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
Status:
Not yet recruiting
Trial end date:
2023-09-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat
for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release
Syndrome (SCRS) in COVID-19 patients.